
Oncology NEWS International
- Oncology NEWS International Vol 12 No 2
- Volume 12
- Issue 2
SuperGen Submits First NDA Module for Pancreatic Cancer Drug
DUBLIN, California-Super-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.
DUBLIN, CaliforniaSuper-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.
Articles in this issue
over 23 years ago
Some Activity for Gefitinib in Heavily Pretreated Breast Cancerover 23 years ago
Brachytherapy Results Similar for Blacks, Whitesover 23 years ago
Dose-Dense Chemo Ups Survival in Node+ Breast Cancerover 23 years ago
MR Spectroscopy IDs Breast Cancers, Node Involvementover 23 years ago
ODAC Wants More Data on Expanded Casodex Indicationover 23 years ago
Two Added to ONI’s Oncology Nursing Editorial Advisory Boardover 23 years ago
Bortezomib Active in Relapsed/Refractory Myelomaover 23 years ago
Telomerase Potential Cancer Biomarkerover 23 years ago
Developing Targeted Therapy More Difficult Than AnticipatedNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































